(Q35675529)

9 August 2017

1 reference

title

Induction of clinical autoimmune disease by therapeutic interferon-alpha (English)

1 reference

9 August 2017

1 reference

2

Leonard Calabrese

1 reference

9 August 2017

Carmen Gota

1

1 reference

9 August 2017

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

36

1 reference

9 August 2017

issue

8

1 reference

9 August 2017

page(s)

511-518

1 reference

Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Treatment of hepatitic C virus infection after the French 2002 Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Advances in the treatment of hairy-cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Cancer immunotherapy: the interferon-alpha experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Immune Interferon in the Circulation of Patients with Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Systemic lupus erythematosus and the type I interferon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Autoimmune disease complicating antiviral therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Association of the B-cell alloantigen DRw4 with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Rheumatoid arthritis induced by alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

21 January 2018

Etiology of sarcoidosis

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

Interferon-induced Raynaud's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930310001605873

10.1080/08916930310001605873

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference